The hypothesis that the assumption of a probiotic associated with a prebiotic (Flortec, Bracco; one sachet contains: Lactobacillus paracasei B21060 5 9 10 9 cells + arabinogalctan 1243 mg + oligo-fructosaccharides 700 mg + L-glutamine 500 mg) could improve the quality and quantity of spermatozoa in idiopathic oligoasthenoteratospermia (iAOT) patients to a larger extent than a control substance (starch) was tested. Forty-one patients with no chromosomal aberrations were randomized into two groups: 20 received Flortec, one sachet per day for 6 months, whereas 21 received the control substance. The following data were collected: clinical history, scrotal Doppler scans, Y microdeletion, karyotype and cystic fibrosis screens, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), testosterone (T), and prolactin (PRL) levels, and two semen analyses. Both the Flortec and the starch groups underwent two semen analyses and one FSH, LH, T, E2, and PRL measurement in the blood, at the beginning of the study, and after 6 months. The comparisons were carried out using a non-parametric (Wilcoxon signed rank) test. The side effects were assessed and compared using the chi-squared test. Group 1 (Flortec) had their sperm count improved: volume of the ejaculate (median from 2.4 to 3.1 mL; p < 0.01), sperm concentration (median: from 15.2 9 10 6 /mL to 28.3 9 10 6 /39 mL; p < 0.01), progressive motility (median: from 16.2 to 42.0%; p < 0.01), and the percentage of typical forms (median: from 7 to 16.3%; p < 0.01); in addition, their FSH, LH, and T levels improved (p < 0.01), while those of E2 and PRL did not. Group 2 (control substance) had no modification in 42 of the parameters studied. There were no side effects in either group. These data showed that Flortec constitutes a safe therapy for improving the volume of the ejaculate and the quality/quantity of spermatozoa in iOAT patients.
INTRODUCTION
Male idiopathic oligoasthenoteratospermia (iOAT), defined as having a seminal quality below normozoospermia generated by defective spermatogenesis of no known etiology, is regarded as undetectable using common laboratory methods and affects approximately 30% of infertile men (Cavallini, 2006) . Therapy for iOAT is commonly regarded to be empiric because iOAT has multiple origins (Cavallini et al., 2008) and, in current outpatient clinical practice, it is not possible to define the exact etiology of the spermatogenetic disorder of each iOAT patient. For the most part, the following therapies have been studied: aromatase inhibitors when total testosterone (T)/17-beta-2-estradiol (E2) is <10 (Cavallini et al., 2013) , antioxidants (Showell et al., 2014) , and follicle-stimulating hormone (FSH) (Garolla et al., 2014) .
The first author of this article (Carlo Maretti) noticed, by chance, that three iOAT patients who assumed a probiotic associated with a prebiotic (Flortec, Bracco, Milano, Italy) , one sachet per day owing to the disorder of their intestinal bacterial flora, had their sperm quality/quantity improved. Thus, the authors began the current double-blind pilot prospective controlled study to test the hypothesis that Flortec administration to iOAT patients improves the quality/quantity of spermatozoa to a larger extent than a control substance.
MATERIAL AND METHODS
The study was authorized by the institutional review board (IRB) of GynePro (Bologna, Italy), and the trial was registered with number 2016-1 at the following website http://www.controlled-trials.com. Patient recruitment began on 2 January 2015 and finished on 31 January 2016. Written informed consent was obtained from each patient. This was a multicenter, randomized, doubleblind, control substance (starch)-controlled study.
Patients
The studied patients were the male partners of infertile couples (World Health Organization, 2010) . World Health Organization (2010) guidelines do not provide a sharp cut-off for sperm count reference values; however, clinical reference values are required for comparison with the values obtained from the patient being assessed in order to define the population to be studied. Non-parametric descriptions of semen analysis appear to be more appropriate than parametric tests (Cooper et al., 2010) ; therefore, the 15th percentile was chosen as a cut-off, according to Junqing et al. (2002) and Cooper et al. (2010) , because 15% of the men in the population were infertile. Thus, 80 of the patients with the following seminal characteristics were included: sperm concentration <30 9 10 6 /mL, percentage of progressive motile spermatozoa <45%, percentage of typical forms <7%, ejaculated volume <2.2 mL, and total ejaculated spermatozoa <100 9 10 6 (Cooper et al., 2010) .
The patients were randomly assigned to one of the two groups to receive either Flortec (Bracco) or a control substance (alimentary starch). The Flortec composition was the following: arabinogalactan 1243 mg, fructose 500 mg, fructo-oligosaccarides 700 mg, L-glutamine 500 mg, raspberry flavoring, non-soluble alimentary fiber 500 mg, Lactobacillus paracasei 86 B21060 <5 9 10 9 colony forming units (CFUs), silicium dioxide, vanilla flavoring, black carrot amphocianines, Carthamus extract, citric acid, and sucralose (Sirtori, 2011) . The IRB reviewed the unblinded data for patient safety; there were no interim analyses for efficacy. Non-smoker infertile men affected by iOAT were considered to be the candidates for the study. Eligible patients were those with normal semen appearance, consistency, liquefaction, volume, and pH. Patients were not admitted to the study if any of the following criteria were present: refusal to participate in the study (5 patients); seminal white blood cell concentration >10 6 /mL or a positive seminal cultural analysis or positive urethral swab chlamydia test (6 patients); drug, tobacco, or alcohol abuse (8 patients); ongoing medical treatment (gonadotropins, anabolic steroids, cancer chemotherapy, non-steroidal anti-inflammatory drugs) (3 patients); dropout during the course of the study (3 patients); previous cancer radiotherapy or chemotherapy (2 patients); palpable varicocoele (10 patients); X-ray exposure in the previous 8 months (3 patients); Y chromosome microdeletion (1 patient); and karyotype alterations (0 patients); T/E2 < 10 (4 patients) (Koscinski et al., 2007; Cavallini et al., 2013) .
Clinical history, two WHO 2010 sperm analyses (World Health Organization, 2010), physical examination, bilateral scrotal Doppler scans, blood hormonal levels, FSH, luteinizing hormone (LH), estradiol (E2), T 103 (testosterone), PRL (prolactin), and genetic assessment (the latter when sperm concentration was <5 9 10 6 /mL: karyotype, Y microdeletion, and cystic fibrosis screening) were carried out on each patient. The patients were randomly assigned to one of the two groups to receive the active drug (Flortec, Bracco), one sachet (Group 1), or a control substance (Group 2) (one sachet containing 100 mg of alimentary starch once a day) for 6 months.
The dosage of the active drug was assessed on the basis of previous preparation tests, carried out by collecting and assessing two semen samples, one before and one after Flortec administration. One sachet was administered once a day to one group of 10 iOAT patients and one sachet was administered twice a day to another group of 10 iOAT patients, both for a period of 6 months. The high variability of sperm parameters and the need to complete preparation tests quickly, testing not more than 10 patients/group (Armitage et al., 2002) , compelled us to consider real improvement of sperm parameters in the course of preparation tests to be an increase of more than double the value of the probability in order to be markedly different when calculated with the Poisson discrete distribution of probability corrected for continuity. Thus, the beneficial effects of the active drug were assessed in terms of number of patients who had their sperm concentration, percentage of progressive motile sperm, sperm volume and percentage of typical forms improved. As all patients in both groups improved their sperm count in all the variables assessed, either by assuming one sachet per day or two sachets per day of Flortec, the beneficial effects of one or two sachets were considered identical. As a result, a one sachet once a day dosage was adopted.
Each patient delivered two semen samples, the abstention time before delivering each sample was 3 days for each patient, once at the beginning of the study and once after 6 months of assumption of either the control substance or the active drug; these were examined according to the World Health Organization (2010) criteria. The patients had their blood FSH, LH, T, E2, and PRL assessed before and after the administration of the active drug or the control substance. All patients had protected intercourse for 6 months. The side effects of the assumption of the active drug or the control substance were also recorded.
Semen analysis
Each patient delivered two semen samples; each was assessed according to the World Health Organization (2010) guidelines. The semen samples were collected by masturbation at the laboratory. Within the first 5 min after ejaculation, the specimen containing the ejaculate was placed in an incubator (37°C) for liquefaction. Assessment of appearance, liquefaction, viscosity, pH, and volume were carried out within 30 min.
• Appearance: Semen analysis began with an inspection soon after liquefaction, at 30 min. A normal liquefied semen sample has a homogeneous, gray opalescent appearance (World Health Organization, 2010).
• Liquefaction was assessed macroscopically with continuous rotation of the sample container on a two-dimensional shaker in an incubator set at 37°C. The liquefaction was judged as normal when it occurred completely within 15 min (World Health Organization, 2010).
• Viscosity: After liquefaction, the viscosity of the sample was estimated by gently aspirating it into a wide bore (1.5 mm diameter) plastic disposable pipette, allowing the semen to drop by gravity, and observing the length of any thread. Normal viscosity samples were defined as those samples which left the pipette in small discrete drops forming a thread not more than 2 cm long (World Health Organization, 2010).
• Semen volume was measured by weighing the sample in the pre-weighed, clean, disposable container in which it was collected, assuming the density of semen to be 1 g/mL (World Health Organization, 2010) . A volume >2.2 mL was judged as normal (see above).
• The pH was measured after liquefaction at a uniform time (i.e., 30 min) by spreading a drop of semen onto the pH paper. When the color of the impregnated zone became uniform (<30 sec), it was compared with the calibration strip to read the pH; a pH of 7.2-8.0 was regarded as the normal range (World Health Organization, 2010).
The semen samples were left to liquefy at 37°C for 30 min. Immediately after liquefaction, a drop of the well-mixed specimen was placed on a clean glass slide, covered with a coverslip, and left for a few minutes. The preparation was examined under a magnification of 1009 and 4009.
• Sperm motility: Motility assessment was carried out on two samples from the same ejaculate, observing at least 200 spermatozoa in each, using at least 10 randomly selected, separated high-power fields. The motility of each spermatozoa was graded according to whether it showed progressive motility, non-progressive motility, or immotility. Each ejaculate was evaluated for sample variability using Pearson coefficients. As values >0.90 and <0.93 were obtained, the differences between the two samples did not need any additional analyses.
• Sperm concentration: Depending on the estimated sperm concentration, a 1 : 10, 1:20, or 1:100 dilution of the semen sample was made with the use of a glass tuberculin syringe using Ham F10 + 10% BSA medium. An improved double-rule Neubauer hemocytometer was used for counting the spermatozoa. Each sample underwent two dilutions. The difference between the two dilutions was not >10% for low concentrations and not >20% for concentrations >60 9 10 6 /mL.
• Percentage of typical forms: To assess the morphology, two semen smears from each patient were stained at the laboratory using the Papanicolaou method and assessed for sperm morphology by a single technician. Two hundred sperm cells were analyzed per slide. Initially, 200 spermatozoa from each of the two different locations on the slide were analyzed. If the difference between the percentage of normal spermatozoa in the two areas tested was five percentage points or less, the mean value was calculated. If the difference was more than five percentage points, an additional 200 spermatozoa were evaluated from a third location on the slide, and the median of all three values was used. The mean value of the two smears was used. Strict criteria were adopted to define the 'normal spermatozoon'. Borderline forms were considered abnormal.
Endpoints and statistical analysis
With respect to the efficacy of Flortec, the primary endpoint was an improvement in the volume of the ejaculate and of sperm concentration, motility morphology, and total ejaculated spermatozoa. The secondary endpoint was to detect differences between pre-and post-Flortec or starch administration in blood levels of FSH, LH, T, E2, and PRL. The differences between the unmatched groups were assessed using the Mann-Whitney rank test, and the differences between before and after (matched groups) therapy were assessed using the Wilcoxon signed rank, each test corrected for the number of samples delivered (two samples) (Armitage et al., 2002) . The levels of significance Table 2 Comparisons between sperm concentration, motility, morphology, volume of the ejaculate, and blood levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (T), prolactin (PRL), and 17-beta-2-estradiol (E2) at the beginning of the study and after a 6-month administration of Flortec (Bracco), one sachet per day (Lactobacillus paracasei B21060 5 9 10 9 cells + arabinogalactan 1243 mg + oligo-fructosaccharides 700 mg + L-glutamine 500 mg) (Group 1), or a control substance (alimentary starch) (Group 2) Data are shown as median values and the ranges are in parentheses. The differences between the unmatched groups were assessed using the Mann-Whitney rank test and the differences between before and after (matched groups) therapy were assessed using the Wilcoxon signed rank test, each test corrected for the number of samples delivered (two samples).
maintained an overall p value of 0.01 and were calculated according to the O'Brien-Fleming early stopping boundary for the endpoint (Tamhane et al., 2010) . The side effects were compared between the two groups using the chi-squared test (Armitage et al., 2002).
Procedures to ensure blindness and randomization Randomization was carried out using an online randomizator: https://www.randomizer.org/. Blindness of drug delivery was ensured with the use of color-coded sachets, and blindness of the seminal examination was ensured by coding each sample 
Millions
Total ejaculated spermatozoa Figure 1 Comparisons between sperm concentration, motility, morphology and volume of the ejaculate and after a 6-month administration of Flortec â (Bracco) one sachet once a day (Lactobacillus paracasei B21060 5 9 10 9 cells + arabinogalactan 1243 mg + oligo-fructo-saccharides 700 mg + L-glutamine 500 mg). Each or patient delivered two semen samples before and after with a number. Nurses delivered the active drug and the control substance in anonymous color-coded sachets; the nurses were blind to the delivery of the color code of the bags and the biologists were blind to the code number of the seminal examinations performed. All study personnel and participants were blind to treatment assignment for the duration of the study. Only the GynePro IRB saw the unblinded data in order to alert physicians in case of major side effects, but this was never necessary, and no one from the IRB had any contact with the study participants. The color and number codes were disclosed at the end of the study (Turner et al., 2012) .
RESULTS
Forty-six patients were eligible for participation in the study: 22 were randomly assigned to receive the active drug (Group 1) and 24 the starch (Group 2). Two patients in Group 1 violated the protocol, and three dropped out from Group 2. A phone call indicated that, in three cases, a transfer of residence occurred and, in the last case, there was a couple conflict. Thus, 20 patients treated with the active drug and 21 treated with the control substance were studied. Table 1 shows the baseline demographic and clinical characteristics for each group. No significant differences emerged. Table 2 summarizes the results of each study group, that is, the volume of the ejaculate, sperm concentration, sperm motility, percentage of typical forms, and blood level of FSH, LH, PRL, T, and E2 before and after a 6-month administration of Flortec or starch (Group 2). Volume of the ejaculate, sperm concentration, sperm motility, number of ejaculated spermatozoa, and percentage of typical forms significantly improved in Group 1 patients at 6 months, while in Group 2, these parameters did not improve (see Fig. 1 ). The levels of FSH, LH, and T increased in Group 1, while E2 and PRL did not. Group 2 had no hormone significantly improved. Side effects were absent in both groups.
DISCUSSION AND CONCLUSION
These data showed that Flortec is safe for improving the volume of the ejaculate, the sperm concentration, the number of ejaculated spermatozoa, the motility, and the percentage of typical forms when administered to iOAT patients. Furthermore, Flortec administration increased FSH, LH, and T blood levels.
The authors began this study with the intention that this study would be a forerunner of future research. Thus, the aim was to ascertain that Flortec administration to iOAT patients improves the sperm count and the semen volume to a larger extent than a control substance. From the beginning of this study, the authors adopted a study design and maintained a p < 0.01 level of significance using early stopping rules (Tamhane et al., 2010; Turner et al., 2012) .
Flortec contains a number of non-adsorbable sugars which carry out their pharmacological activity on contact with bowel ambient and Bacillum paracasei (Sirtori, 2011) ; thus, the authors chose alimentary starch as a control substance owing to its nature as a non-adsorbable harmless polysaccharide, completely different from the polysaccharides contained in Flortec, and free of any pharmaceutical activity which is currently used as a bulking agent.
At present, it is unknown what the mechanism of action of the active drug is; Flortec administration increased blood gonadotropins and T, which stimulate spermatogenesis (Cavallini, 2006; Garolla et al., 2014) . One hypothesis regarding iOAT etiology sustains that it might be generated by 'subtle' alterations of the pulsatile secretion of gonadotropins and testosterone (Cavallini, 2006) . It has been accepted that Flortec interacts with kisspeptin hypothalamic pulsatile secretion; kisspeptin signaling is of key importance for human fertility, regulating the gondatropin releasing hormone (Liu & Herbison, 2016 ). An additional hypothesis regarding iOAT genesis indicates an increased concentration of reactive oxygen species in the seminal plasma as an etiology (Cavallini, 2006) . It has been accepted that pro-+ prebiotics, such as Flortec, optimize the free radical concentration in the seminal fluid (Hou et al., 2013; Wang et al., 2016) . Finally, subtle prostatic alterations are considered to be a third cause of iOAT (Cavallini, 2006) : Flortec improves the prostatic microenvironment, ameliorating the intestinal flora (Uranga et al., 2016) . In this way, Flortec seems to possess all the necessary characteristics for improving the quality/quantity of spermatozoa and the volume of the ejaculate of iOAT patients.
The authors considered the following corollaries, which emerged in the course of the study, as interesting. Five of the 20 patients treated with the active drug fathered a child, whereas no control substance-treated patient fathered a child. DNA fragmentation was assessed using the sperm chromatin dispersion (SCD) test (Wdowiak et al., 2015) in four patients treated with the active drug, and in four treated with the control substance. The SCD test data showed significant improvement in all the patients treated with Flortec (percentage of spermatozoa with fragmented DNA before Floretec administration: 45%, 39%, 44%, 65%; percentage of spermatozoa with fragmented DNA after Flortec administration: 22%, 25%, 20%, 21%), while the data did not significantly change in the patients who assumed the control substance (percentage of spermatozoa with fragmented DNA before starch administration: 49%, 48%, 62%, 58%; percentage of spermatozoa with fragmented DNA after starch administration: 41%, 45%, 66%, 55%).
All of these data, associated with the low cost of the active drug and its easy administration, legitimized our intention to carry out this study on a larger scale in order to assess the mechanism of action of Flortec, its efficacy in achieving spontaneous pregnancies, in improving DNA fragmentation, and in improving outcomes of assisted reproduction techniques.
